文献速递腹部技术与安全CT

肌少症对晚期肝细胞癌患者全身靶向治疗反应的影响

Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma.
PubMed 文献 · Abdom Radiol (NY) · 2020-09-24

回顾性分析36例接受免疫检查点阻断或酪氨酸激酶抑制剂治疗的晚期肝细胞癌患者,于治疗前CT测量T12水平竖脊肌面积计算骨骼肌指数,并与治疗反应(总生存≥1年或肿瘤坏死>50%)进行相关性分析,发现肌少症与生存及坏死减少相关,T12骨骼肌指数在女性阈值为7.21-8.23(AUC=1,p=0.037)、男性阈值为11.47(AUC=0.83,p=0.015)时与治疗反应相关。

要点

  • 治疗前CT于T12水平测量竖脊肌面积计算骨骼肌指数,可用于评估肌少症。
  • 女性T12骨骼肌指数阈值7.21-8.23时与治疗反应相关(AUC=1,p=0.037)。
  • 男性T12骨骼肌指数阈值11.47时与治疗反应相关(AUC=0.83,p=0.015)。

核心结论

  • 肌少症与接受全身靶向治疗的晚期肝细胞癌患者生存期缩短及肿瘤坏死减少相关。
  • 肌少症可能有助于预测晚期肝细胞癌靶向治疗的结局。

研究设计与样本

  • 回顾性研究,经机构审查委员会批准,纳入36例经活检证实的晚期肝细胞癌患者,均接受全身靶向治疗。
  • 治疗方式为免疫检查点阻断(n=25)或酪氨酸激酶抑制剂(n=11)。
  • 于治疗前CT上测量T12水平竖脊肌面积,按公式SMI=竖脊肌面积(cm²)/身高(m²)计算骨骼肌指数。
  • 治疗反应定义为总生存期≥1年(非手术患者)或肝细胞癌坏死>50%(手术患者)。
  • 采用受试者工作特征曲线及曲线下面积分析,p<0.05为统计学显著。

诊断标准与关键数值

  • 采用T12水平骨骼肌指数预测治疗反应,女性阈值7.21-8.23时AUC=1(p=0.037)。
  • 采用T12水平骨骼肌指数预测治疗反应,男性阈值11.47时AUC=0.83(p=0.015)。
  • 男性年龄≥60岁时相关性增强,AUC=0.87(p=0.023)。
  • 治疗反应定义为总生存期≥1年(非手术患者)或肝细胞癌坏死>50%(手术患者)。
  • 男性平均身高1.7 m(±0.1)、平均骨骼肌指数11.4(±3.6);女性平均身高1.7 m(±0.1)、平均骨骼肌指数8.2(±1.9)。

临床应用与阅片要点

  • 治疗前CT可于T12水平测量竖脊肌面积计算骨骼肌指数,用于评估肌少症。
  • 肌少症可能有助于预测晚期肝细胞癌患者对全身靶向治疗的反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Sarcopenia is an independent prognostic indicator for hepatocellular carcinoma (HCC). Our objective was to determine the effect of sarcopenia on response to systemic targeted therapy in patients with advanced HCC.

MATERIALS AND METHODS: This was a retrospective, Institutional Review Board approved study of 36 patients on systemic targeted therapy with immune checkpoint blockade (n = 25) or tyrosine kinase inhibitor (n = 11) for biopsy-proven advanced HCC. Skeletal muscle index (SMI) was calculated from erector spinae muscle area (SMA) at the level of T12 on pretreatment CT: [SMI = SMA (cm2)/height (m2)]. SMI was compared to treatment response defined as overall survival ≥ 1 year (nonsurgical patients) or > 50% HCC necrosis (surgical patients). Receiver operating characteristic curve and area under the curve was used for analysis with p < 0.05 for statistical significance.

RESULTS: Median age of men and women was 66.5 years (range 32-83) and 70 years (range 54-78), respectively. Liver disease etiology was nonalcoholic steatohepatitis (n = 9), hepatitis C (n = 10), hepatitis B (n = 5), alcohol (n = 3) and unknown (n = 9). Mean (± SD) height and SMI for men were 1.7 m (± 0.1) and 11.4 (± 3.6); values for women were 1.7 m (± 0.1) and 8.2 (± 1.9). Treatment was withdrawn in five patients due to treatment intolerance. Response occurred in 10/31 (32.3%) patients (23 men, 8 women). T12SMI correlated with treatment response using a threshold of 7.21-8.23 for women (AUC = 1; p = 0.037), and 11.47 for men (AUC = 0.83; p = 0.015); correlation was increased for men ≥ 60 years, (AUC = 0.87; p = 0.023).

CONCLUSION: Sarcopenia was associated with reduced survival and HCC necrosis in patients treated with systemic targeted therapy.

CLINICAL RELEVANCE: Sarcopenia may help in predicting outcomes to targeted therapy in advanced HCC.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Qayyum A, Bhosale P, Aslam R, et al. Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdom Radiol (NY). 2020. PMID: 32974761. doi:10.1007/s00261-020-02751-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。